Search Medical Condition
Please enter condition
Please choose location from dropdown

Pamplona, Navarra, Spain Clinical Trials

A listing of Pamplona, Navarra, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (130) clinical trials

Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma

Test Product, Dose and Mode of Administration, Duration of Treatment: The study is using a modified 3+3 design and has 2 parts. First (Lead-In phase), the MTD for the Nivo-Pom-dex combination will be determined: Regimen A: The treatment regimen will include Pomalidomide, Nivolumab and low dose dexamethasone. There will be ...

Phase

0.0 miles

Learn More »

A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) as an Adjunctive Therapy in Children and Young Adults With Dravet Syndrome

This is a multicenter, double-blind, parallel-group, placebo-controlled, study to assess the efficacy, safety, and pharmacokinetics of ZX008 when used as adjunctive therapy in pediatric and young adult subjects with Dravet syndrome. Subjects who qualify for the study will be randomized (1:1:1) in a double-blind manner to receive 1 of 2 ...

Phase

0.0 miles

Learn More »

Phase 1 Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma

The primary purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527 (Part 1), and to assess the safety and tolerability of H3B-6527 as a single agent administered orally (Part 2) in participants with advanced hepatocellular carcinoma (HCC) or Intrahepatic ...

Phase

0.0 miles

Learn More »

Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma

The primary object is to estimate the Objective response rate (ORR) based on investigator assessment using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 of the TITAN regimen in untreated (1st line) and pretreated (2nd line) subjects with International Metastatic RCC Database Consortium (IMDC) intermediate and high risk, advanced Renal ...

Phase

0.0 miles

Learn More »

Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy

The purpose of this study is evaluate the efficacy of INCB054828 in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.

Phase

0.0 miles

Learn More »

Post-Market Clinical Follow-Up Study to Confirm Clinical Performance and Safety of the Codman Enterprise 2 Vascular Reconstruction Device in the Endovascular Treatment of Intracranial Aneurysms

The objective of this Post-Market Clinical Follow-up (PMCF) is to confirm the performance and safety of the Codman Enterprise 2 when used in conjunction with endovascular coil embolization of ruptured or non-ruptured intracranial aneurysms.

Phase N/A

0.0 miles

Learn More »

Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma

This clinical trial is a multicenter Phase II study designed to evaluate the efficacy and toxicity of an intensive therapeutic approach in 90 patients with asymptomatic high risk multiple myeloma (SMM). 1. - Patients will receive an induction treatment consisting of 6 cycles of carfilzomib, lenalidomide and low-dose dexamethasone (KRd): ...

Phase

0.0 miles

Learn More »

GEM-CLARIDEX: Ld vs BiRd

BiRd Arm Subjects on the BiRD arm will receive clarithromycin, Revlimid (lenalidomide), and dexamethasone in 28-day cycles. Dosing is as follows: Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle. If a dose of clarithromycin is missed, it should be taken as soon as possible on the ...

Phase

0.0 miles

Learn More »

Pembrolizumab (MK-3475) in MM Patients With Residual Disease

Multiple Myeloma (MM) is a B cell malignancy characterized by the presence of bone marrow infiltration by clonal plasma cells that generally secrete a monoclonal component in the serum or urine. It is the second most frequent hematological malignancy, after non-Hodgkin lymphomas, and accounts approximately for a 10% of all ...

Phase

0.0 miles

Learn More »

A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

A Phase 2 Study to evaluate the Efficacy and Safety of ACP-196 (acalabrutinib) in Subjects with Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

Phase

0.0 miles

Learn More »